Novo Nordisk criticized the research, saying it had insufficient evidence linking semaglutide to the disorder.
Topline
People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA Network, which Novo Nordisk has criticized for being insufficient.Key Facts
A study of nearly 1,700 patients who either used semaglutide—the active ingredient in Ozempic and Wegovy—or another drug for treating Type 2 diabetes or obesity found a possible link between semaglutide and nonarteritic anterior ischemic optic neuropathy (NAION), researchers said.
Semaglutide is associated with a four times higher risk of NAION when used for treating Type 2 diabetes and a seven times higher risk when used for obesity, according to the study.
Among the 710 patients with Type 2 diabetes, the rate of developing NAION was 8.
